4.64

6.16% -0.31

Astria Therapeutics Inc (ATXS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Astria Therapeutics Inc stock is traded at $4.64, with a volume of 180.04K. It is down -6.16% in the last 24 hours and down -9.98% over the past month. Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Previous Close:

$4.95

Open:

$4.92

24h Volume:

180.04K

Relative Volume:

0.41

Market Cap:

$261.84M

Revenue:

Net Income/Loss:

$-72.89M

P/E Ratio:

-1.9174

EPS:

-2.42

Net Cash Flow:

$-68.47M

1W Performance:

+18.49%

1M Performance:

-9.98%

6M Performance:

-55.29%

1Y Performance:

-48.45%

1-Day Range:

$4.54

$4.92

1-Week Range:

$3.83

$4.98

52-Week Range:

$3.555

$12.92

Astria Therapeutics Inc Stock (ATXS) Company Profile

Name

Astria Therapeutics Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

617-349-1971

Address

22 BOSTON WHARF ROAD, BOSTON

Employee

Twitter

Next Earnings Date

2025-03-11

Latest SEC Filings

ATXS's Discussions on Twitter

Compare ATXS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATXS Astria Therapeutics Inc	4.64	230.25M	0	-72.89M	-68.47M	-2.42
ONC Beone Medicines Ltd Adr	246.59	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	443.68	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.32	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	80.89	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	493.00	64.44B	14.09B	4.50B	2.96B	39.28

Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Jan-31-25	Initiated	JMP Securities	Mkt Outperform
Jul-29-24	Initiated	TD Cowen	Buy
Mar-28-23	Initiated	Evercore ISI	Outperform

Astria Therapeutics Inc Stock (ATXS) Latest News

May 28, 2025

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference - Business Wire

May 28, 2025

May 26, 2025

Janus Henderson Group PLC Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 26, 2025

May 23, 2025

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficien - GuruFocus

May 23, 2025

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop - Business Wire

May 23, 2025

Northern Trust Corp Has $4.10 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 23, 2025

May 22, 2025

Astria Therapeutics to Present at Upcoming Eastern Allergy Confe - GuruFocus

May 22, 2025

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference | ATXS Stock News - GuruFocus

May 22, 2025

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - Business Wire

May 22, 2025

May 21, 2025

Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.00 - Defense World

May 21, 2025

May 18, 2025

Price T Rowe Associates Inc. MD Buys 2,878 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 18, 2025

Astria Therapeutics’ (ATXS) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World

May 17, 2025

May 16, 2025

FMR LLC Reduces Holdings in Astria Therapeutics Inc - GuruFocus

May 16, 2025

(ATXS) Technical Data - news.stocktradersdaily.com

May 16, 2025

Astria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 15, 2025

Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail

May 15, 2025

Astria Therapeutics Reports Increased Loss Amid Rising R&D Costs - TipRanks

May 15, 2025

May 14, 2025

Analyst Reiterates Overweight Rating for ATXS with Stable Price Target | ATXS Stock News - GuruFocus

May 14, 2025

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation - Yahoo Finance

May 14, 2025

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update | ATXS Stock News - GuruFocus

May 14, 2025

Astria Therapeutics (ATXS) Advances Navenibart as Groundbreaking HAE Therapy | ATXS Stock News - GuruFocus

May 14, 2025

Astria Therapeutics (ATXS) Sees Price Target Adjustment Amid Ong - GuruFocus

May 14, 2025

Astria Therapeutics price target lowered to $25 from $26 at Citizens JMP - TipRanks

May 14, 2025

May 13, 2025

Astria Therapeutics Q1 Operating Expenses USD 36.995 Million - marketscreener.com

May 13, 2025

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Business Wire

May 13, 2025

Astria Therapeutics, Inc. SEC 10-Q Report - TradingView

May 13, 2025

Tower Research Capital LLC TRC Purchases 2,766 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 13, 2025

May 09, 2025

Is Astria Therapeutics, Inc. (ATXS) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey

May 09, 2025

Wells Fargo & Company MN Acquires 7,563 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

May 09, 2025

May 08, 2025

10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey

May 08, 2025